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Abstract
It has been nearly 70 years since the discovery that strict adherence to a diet low in phenylalanine prevents severe neurological sequelae in
patients with phenylalanine hydroxylase deﬁciency (phenylketonuria; PKU). Today, dietary treatment with restricted phenylalanine intake
supplemented with non-phenylalanine amino acids to support growth and maintain a healthy body composition remains the mainstay of
therapy. However, a better understanding is needed of the factors that inﬂuence N balance in the context of amino acid supplementation. The
aim of the present paper is to summarise considerations for improving N balance in patients with PKU, with a focus on gaining greater
understanding of amino acid absorption, disposition and utilisation. In addition, the impact of phenylalanine-free amino acids on 24 h blood
phenylalanine/tyrosine circadian rhythm is evaluated. We compare the effects of administering intact protein v. free amino acid on protein
metabolism and discuss the possibility of improving outcomes by administering amino acid mixtures so that their absorption proﬁle mimics
that of intact protein. Protein substitutes with the ability to delay absorption of phenylalanine and tyrosine, mimicking physiological absorption
kinetics, are expected to improve the rate of assimilation into protein and minimise ﬂuctuations in quantitative plasma amino acid levels. They
may also help maintain normal glycaemia and satiety sensation. This is likely to play an important role in improving the management of
patients with PKU.
Key words: Phenylalanine: Phenylketonuria: Amino acids: Absorption: Amino acid mixtures: Protein synthesis: Nitrogen
balance
Introduction
Phenylalanine hydroxylase (PAH) deﬁciency(1), also known as
phenylketonuria (PKU), causes accumulation of neurotoxic
levels of the substrate phenylalanine (Phe) and a relative deﬁcit
of the product tyrosine (Tyr)(2). Unless treated early and con-
tinuously with a Phe-restricted and Tyr-supplemented diet(3),
children experience cognitive impairment(4), while adolescents
and adults may develop deﬁcits in executive function, attention
and social skills(5–8). Dietary treatment with restricted Phe intake
remains the mainstay of therapy for PKU, although a subset of
patients usually with mild or moderate PKU may respond to
treatment with pharmacological doses of the PAH cofactor tet-
rahydrobiopterin (BH4)
(3,9). The aim of the present paper is to
review considerations for improving N balance in patients with
PKU, with a focus on gaining a better understanding of amino
acid absorption, disposition and utilisation.
Dietary management of phenylketonuria
Aims of dietary treatment
The primary aim of dietary treatment is to prevent adverse neu-
rocognitive and psychological outcomes by restricting and titrat-
ing the intake of protein from natural foods to maintain blood Phe
levels within the guideline-established range that prevents
adverse outcomes while providing enough Phe to support protein
synthesis and avoid catabolism(3,9). There is general consensus on
the importance of meticulous control of blood Phe levels within a
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l)(3,9,10). For patients above the age of 12 years (exception pre-
conception and pregnancy), the European guidelines consider
120–600 μmol/l to be safe throughout adolescence and adult-
hood(3), while US guidelines advocate 120–360 μmol/l throughout
life(10). Protein substitutes have an important role in helping
achieve optimal metabolic control.
The second aim of dietary management is to maintain a
healthy nutritional status by providing sufﬁcient non-Phe amino
acids, energy and other nutrients to support physiological
protein synthesis and counterbalance catabolism, without pro-
viding excess energy. N and essential amino acid requirements
are met with a Phe-free amino acid mixture containing vitamins
and other essential nutrients and the addition of special low-
protein modiﬁed foods provides a necessary energy
source(11,12). The specialist dietitian and metabolic physician
manage dietary treatment to maintain appropriate blood Phe
levels in response to metabolic changes, while ensuring that
other nutritional requirements are being satisﬁed to support
normal growth and development in children and a healthy
body composition in all patients(13).
Notwithstanding the theoretical effectiveness of dietary
treatment, its actual success depends on providing a diet that is
acceptable and practical to the patient. Subjective factors that
can hinder acceptance include poor palatability, disagreeable
smell, or textures, lack of dietary variety and food neopho-
bia(14). Adherence with protein substitutes that must be con-
sumed at least three times a day throughout life is a particular
challenge. Socially acceptable, appropriate food choice is par-
ticularly important for improving adherence as patients move
from childhood to adolescence, as they have more responsi-
bility for managing their treatment and are exposed to new food
choices and peer pressure outside the home(15).
Protein requirement
In PKU, when the protein requirement is met primarily with a
Phe-free amino acid mixture, the protein equivalent amount of
amino acids should be increased because of poor retention(15).
This higher requirement may have both a physiological cause,
related to the oxidation of excess free amino acids due to their
rapid, non-physiological absorption(16–18), and perhaps a
pathological cause, related to higher needs imposed by the
condition itself, in the form of increased catabolism. Few studies
have addressed this latter point. Van Rijn et al.(19) found no
difference in protein metabolism between adults with PKU and
matched healthy volunteers using an L-[1-13C]valine tracer
method. In this study, six patients with PKU received amino
acids equivalent to 0·96 g protein/kg per d (120% of the WHO
recommended daily allowance)(20), while the six healthy
volunteers received 0·8 g intact protein/kg per d (100% of the
recommended daily allowance). The 20% increase in patients
with PKU was administered to account for inefﬁcient absorp-
tion/utilisation. The results suggest that, at least in adults with
PKU, the increased requirement for amino acids results from
reduced retention rather than an increase in metabolic
requirement. In children, however, Turki et al.(21) used the
indicator amino acid oxidation technique to study four patients
with mild PKU ranging in age from 9 to 18 years, ﬁnding that
their protein requirement was 1·85 g/kg per d, considerably
higher than the recommended amount for healthy children(21)
and higher than the recommendation for children with
PKU(3,9,22,23). This may reﬂect methodological differences
between older N balance studies that inform guidelines and the
more sensitive isotope methods. Moreover, in a 6-week ran-
domised, cross-over study conducted in twenty-ﬁve children
aged 2–10 years (median 6 years), administering a higher
dosage of protein substitute was associated with lower blood
Phe levels(24). Compared with a PKU diet containing the
recommended protein requirement for children (1·2 g/kg per
d), a similar diet with higher protein content (2·0 g/kg per d)
resulted in median blood Phe levels that were 301 μmol/l lower
when measured before breakfast (95% CI 215, 386 μmol/l;
P< 0·001) and 337 μmol/l lower when measured in the evening
(95% CI 248, 431 μmol/l; P< 0·001)(24).
Either of these mechanisms (reduced retention or increased
requirement) justiﬁes the administration of increased amino
acid intake or the use of an amino acid mixture formulated to
achieve physiological absorption and avoid net protein cata-
bolism, which causes the release of Phe and increases blood
Phe concentrations. The current European guidelines suggest
administering 140% of the recommended daily requirement
established for healthy individuals(3), and the most recent US
guidelines suggest administering 150% until age 4 years and
120–140% thereafter(22).
Digestion and absorption of intact protein
All amino acids contain at least one amine and one carboxyl
group, and a speciﬁc side chain that determines the char-
acteristics of the amino acid. In humans, eleven of the twenty
standard amino acids are classiﬁed as either essential, because
they cannot be synthesised (histidine, isoleucine, leucine
(Leu), lysine, methionine, Phe, threonine, tryptophan and
valine), or semi-essential, because they may not be synthe-
sised sufﬁciently in growing children (cysteine and arginine);
these must be obtained from the diet(25). In addition to protein
synthesis, amino acids such as glutamine, tryptophan and Tyr
are precursors for neurotransmitters. Amino acids can also
serve as an energy source(26,27), although this is not their
main role. The amino group is removed via transamination to
α-ketoglutarate and then processed in the urea cycle. Amino
acids are classiﬁed as either ‘glucogenic’, if their catabolism
yields pyruvate or citric acid cycle intermediates that can
generate glucose, or ‘ketogenic’ if their catabolism results in
acetyl- or acetoacetyl-CoA.
Digestion of proteins starts in the stomach, where the low pH
denatures them, removing their secondary structure and
exposing them to cleavage by pepsin. Proteolytic enzymes of
the exocrine pancreas (carboxypeptidase, chymotrypsin, elas-
tase and trypsin) perform most of the digestion in the duode-
num, producing short peptide fragments that are then
processed into di- and tripeptides and free amino acids by
aminopeptidase and dipeptidase on the apical membrane of
enterocytes. Na-dependent amino acid transporters for acidic,
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from the electrochemical Na gradient to transport their sub-
strates across the apical membrane of the enterocyte.
Generally, several amino acids compete for binding to a
shared transporter or exchanger, and different amino acids have
different carrier afﬁnities, depending on the mass of their side
chain and the presence of an electrical charge. Afﬁnity increases
with mass and is also higher for neutral amino acids. The large
neutral amino acids (LNAA) are transported by the LNAA
transporter 1 (LAT1), also known as SLC5A7, for which Phe has
very high afﬁnity. Amino acids are absorbed also as di- and
tripeptides through co-transport with H+ ions via peptide
transporter 1 (PEPT 1; also known as solute carrier family 15
member 1 SLC15A1). With normal protein feeding, most amino
acids enter the enterocytes from the intestinal lumen as pep-
tides that are subsequently hydrolysed to free amino acids in
the cytoplasm(28).
Depending on the metabolic status of the enterocyte,
absorbed amino acids may be utilised for energy, incorporated
into proteins or released from the basolateral membrane into
the hepatic portal circulation via Na-independent transporters.
The N requirement of the intestinal mucosa is high, owing to
rapid cell turnover, production of secretory proteins and a
tendency to use amino acids as an energy source. The meta-
bolic fate of an ingested N source depends also on the kinetics
of amino acid absorption. Indications of this arise from com-
paring the so-called ‘fast’ and ‘slow’ proteins, named in this way
because of their rates of digestion and amino acid absorp-
tion(29,30). The digestion rate appears to be controlled by the
rate of gastric emptying. Whey, a fast protein, remains soluble in
the stomach and passes quickly to the intestine, whereas the
slow protein casein coagulates and is retained longer(31). Fast
proteins result in less N assimilation(29). This observation is
conﬁrmed by a study comparing the kinetics of dietary N after
feeding either intact or hydrolysed casein protein labelled with
15N, which revealed reduced peripheral protein synthesis with
hydrolysed casein (faster)(32).
Free amino acid supplementation
Amino acid absorption
Free amino acid mixtures are formulated to fulﬁl the speciﬁc
requirements of patients with PKU. Administering free amino
acids bypasses the digestive phase, and the absorption proﬁle is
different from that of intact proteins, in that plasma levels of total
and essential amino acids are higher, peak faster and decrease
more quickly (Fig. 1)(17). Administering a free amino acid mix-
ture with a prolonged release mimicking physiological absorp-
tion kinetics is expected to improve the rate of assimilation into
protein and prevent ﬂuctuations in plasma amino acid levels.
Metabolic effects of amino acid absorption rate
Compared with physiological administration of free amino acid
mixtures distributed through the day, bolus administration
increases the amount of N excreted in urine(18), when the rapid
increase in blood amino acids exceeds the capacity of anabolic
processes to incorporate them into nascent proteins. Dangin
et al.(33) examined the effect of protein digestion rate on protein
accretion using 13C-labelled Leu and various fast v. slow protein
meals. They compared casein v. free amino acids mimicking
casein, and whey protein bolus (fast protein) v. repeated dosing
(simulated slow protein)(33). Fast uptake was associated with a
rapid increase in blood amino acids and more oxidation. Pro-
tein retention was greater with slow protein sources (casein
v. free amino acids: 38 (SE 13) v. –12 (SE 11) µmol Leu/kg;
P< 0·01) and with repeated dosing v. whey bolus (87 (SE 25) v. 6
(SE 19) µmol Leu/kg; P< 0·05). Jones et al.(34) compared con-
tinuous enteral nutrition with protein v. free amino acid mix-
tures in isonitrogenous, isoenergetic diets, and found that
patients randomly assigned to receive the free amino acid
mixture had signiﬁcantly higher N loss(34). However, a meta-
bolic study comparing adult patients with PKU fed a protein-
restricted, free amino acid mixture-supplemented diet with
matched healthy subjects receiving a normal diet revealed no
differences in whole-body protein metabolism at a protein
intake of 0·8 g/kg per d(19).
Infusion of increasing amounts of a balanced mixture of free
amino acids (from 0·5 up to 6mg/kg per min) in fasted healthy
young adults resulted in inhibition of protein catabolism, sti-
mulation of protein synthesis and an increase in amino
acid oxidation, depending on plasma amino acid levels attained
(Fig. 2)(35). Even small increases in amino acid concentrations
compared with fasting concentrations inhibited protein cata-
bolism and, in parallel, stimulated protein synthesis as well as
amino acid oxidation. The decrease in protein catabolism was
overruled by the increase in amino acid oxidation and most
notably protein synthesis(35).
Protein synthesis is stimulated both by amino acids and by
insulin. When plasma amino acids levels are artiﬁcially main-
tained at post-absorptive levels (i.e. physiological hyper-
aminoacidaemia), administration of insulin further increases net
protein synthesis and decreases protein catabolism, with no
signiﬁcant change in amino acid oxidation(36).
Protein synthesis increases in the postprandial state because















































Fig. 1. Mean change from baseline in total plasma amino acids after feeding
whole protein (cottage cheese, ––) or an equivalent amount of a free amino
acid mixture with identical amino acid composition (---) in fasting healthy
volunteers (n 10). Adapted from Gropper & Acosta(17).
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plasma amino acids, especially Leu, that work through the
mammalian target of rapamycin (mTOR)(37). Insulin and insulin-
like growth factor 1 increase protein synthesis at the translation
level via mTOR-mediated effects on components of the protein
synthetic pathway, including the eukaryotic initiation factor 4E-
binding protein 1 (4E-BP1) and the ribosomal protein S6 kinase
(p70S6K), both key components of the translation initiation
complex(38). Thus, the anabolic signal from insulin, corre-
sponding to abundant energy (glucose), is an important factor
controlling protein metabolism(39). This underscores the need
for sufﬁcient energy intake to promote anabolism and prevent
an increase in N excretion when free amino acid mixtures are
administered(18,40,41). An optimal protein:energy ratio has been
proposed as 3·0–4·5 g protein/100 kcal (418 kJ), corresponding
to approximately 12–18% of energy from protein(42).
Amino acids themselves stimulate insulin secretion(43).
Branched-chain amino acids, especially Leu, have an insulino-
genic effect when administered together with a glucose solu-
tion, compared with glucose solution alone(44). Amino acids
also stimulate the release of the incretins glucagon-like peptide-
1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP)(45,46), which in turn increase the anabolic response by
promoting insulin secretion(47). The amino acid mixtures used
in the dietary treatment of PKU contain a high level of Leu to
promote anabolism. In healthy subjects, preloading with 9 g of
either whey or soya protein, or a combination of the insulino-
genic amino acids (isoleucine, Leu, lysine, threonine and
valine) before a reference meal signiﬁcantly reduced post-
prandial glycaemia. This correlated with increased incretin and
insulin responses(48). Compared with administration of free
amino acid mixtures, physiological absorption of amino acids
from intact protein represses ghrelin levels to a greater extent,
providing a sense of satiety(40,41).
Thus, in addition to favouring a positive N balance, more
physiological absorption of amino acids in the dietary treatment
of PKU may be expected to help maintain normal glycaemia
and normal sensation of satiety. However, simulating normal
absorption kinetics with existing free amino acid mixtures is
problematic because it would complicate the treatment with
more frequent dosing. When possible, administration of free
amino acid mixtures should coincide with a postprandial state,
in order to favour retention of dietary N.
Disposition of key amino acids in phenylketonuria
Role of the blood–brain barrier
The most severe pathological effects of PKU are in the brain.
The blood–brain barrier (BBB) isolates the brain from ﬂuctua-
tions in blood levels of hormones, nutrients and metabolites,
and provides the stable chemical environment required for
delicate neural processes. The BBB is the result of tight junc-
tions between the endothelial cells of brain capillaries and a
multitude of transporters that regulate the passage of speciﬁc
molecules. The concentration of essential amino acids inside
the brain is approximately ten times lower than in the general
circulation and is determined by the controlled transport of
LNAA across the BBB(49). This is accomplished through LAT1
(SLC7A5/SLC3A2 heterodimer), which has high afﬁnity for the
LNAA precursors important for neurotransmitter and protein
synthesis(50,51). LAT1 is a member of transporter system L,
ubiquitous bidirectional Na-independent exchangers of bran-
ched and aromatic neutral amino acids(52). In BBB endothelial
cells, LAT1 is expressed on both the luminal (blood) and
abluminal (brain) membranes and facilitates the transendothe-
lial transport of LNAA (uptake substrates) in exchange for non-
essential amino acid substrates (antiporter)(53). Cells inside the
brain have a three-fold higher afﬁnity for essential amino acids
compared with the BBB endothelia(54), making the BBB the
limiting transfer step. This system is nearly saturated at phy-
siological blood amino acid concentrations, and is subject to
substrate competition depending on LNAA abundance and
afﬁnity. Phe is the amino acid with the highest afﬁnity for LAT1
and the high Phe level in PKU essentially blocks the uptake of
other LNAA, reducing the synthesis of proteins and neuro-
transmitters in the brain(55,56). The importance of the BBB and
amino acid disposition as a mechanism in the pathophysiology
of PKU is highlighted by the ﬁnding that a minority of patients
with pathologically high blood Phe concentrations have lower
than expected brain Phe levels and normal intelligence quotient
(IQ) without treatment(57–59); however, the mechanism for this
rare and irregular outcome remains unidentiﬁed(60).
Large neutral amino acids
One approach to treating PKU involves administering higher
than normal amounts of non-Phe LNAA in order to overcome
this competition and allow other essential LNAA to enter the
brain(61). Decreasing Phe entrance into the brain by another
LNAA would be accomplished most effectively with Leu (and
isoleucine)(62), but this does not address the entire pathogenesis
of PKU brain dysfunction, and it might also result in increased
brain Leu or isoleucine concentrations, which are both asso-
ciated with inborn errors of metabolism with brain pathophy-
















































Increase in blood amino acids (% of fasting level)
Fig. 2. Effects of graded hyperaminoacidaemia on protein metabolism: a
balanced amino acid solution was infused at 0·5, 1, 2, 4 and 6mg/kg per min for
180 min in eight fasting healthy volunteers, and amino acid oxidation (–♦–),
protein synthesis (–■–) and proteolysis (–▲–) were estimated with [1-14C]
leucine infusion and indirect calorimetry. Redrawn from Giordano et al.(35).
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must be carefully balanced according to amino acid transporter
afﬁnities and importance for brain function. In particular, Tyr
and tryptophan should be included at high levels to promote
normal brain monoaminergic neurotransmitter concentra-
tions(62). Three mechanisms driving the improvement observed
with LNAA administration have been conﬁrmed in a murine
PKU model: LNAA supplementation reduced brain Phe levels,
increased brain levels of non-Phe LNAA and increased neuro-
transmitter levels(63). However, dopamine levels were not nor-
malised in this study, once again indicating the necessity to
carefully balance the composition of the LNAA administered.
Tyrosine
The product of PAH is Tyr, which becomes a conditionally
essential amino acid in patients with PKU(64). Tyr is essential for
protein and dopamine synthesis in the brain. Patients with
uncontrolled PKU have reduced levels of dopamine because
Tyr is not produced from Phe and high blood Phe levels pre-
vent exogenous Tyr from crossing the BBB. Tyr supplementa-
tion may cause blood Tyr levels to ﬂuctuate greatly during the
day in treated patients with PKU(65–69). CV for blood Tyr con-
centrations are about ten-fold higher than those of Phe(69). This
may be due to the small pool of Tyr in patients with PKU and
the relatively high level of Tyr in the free amino acid mixtures
administered in the PKU diet(69). It should be noted that,
although the amino acid mixtures contain high levels of Tyr, it is
not highly soluble, and solutions containing Tyr must be mixed
well before administration. A slower release of free amino acids
allowing a more physiological absorption may also reduce the
amplitude of blood Tyr peaks and overall degree of ﬂuctuation.
Fluctuations in blood phenylalanine levels over 24 h
In healthy subjects, the blood concentrations of individual
amino acids undergo circadian variation, with peak levels
occurring in the evening(70). This rhythm is stable and not
inﬂuenced signiﬁcantly by diet(71). Much of the ingested Phe is
converted to Tyr in the liver, stabilising blood Phe levels, and
maintaining the amplitude of variation generally < 50%(72).
Greater circadian ﬂuctuations in blood Phe levels have been
reported in patients with PKU(65,73,74). These ﬂuctuations may
be more apparent with PAH genotypes that have low/no resi-
dual enzyme activity(75). In addition, it is suggested that BH4 in
pharmacological doses reduces Phe ﬂuctuations in BH4-
responsive patients; however, responsive patients have residual
PAH activity with less severe PKU, and generally have lower
and less variable blood Phe(76,77).
The normal pattern of circadian ﬂuctuations in blood Phe is
inverted in patients with PKU, with the highest levels occurring
in the morning instead because of catabolism triggered by
overnight fasting(65,74). Diurnal ﬂuctuations may also result from
inappropriate distribution of free amino acid mixtures during
the day, with even distribution throughout the day resulting in
more stable Phe levels(73,78); however, administration during
waking hours only is not sufﬁcient to prevent nocturnal cata-
bolism. Fluctuations in blood Phe from day to day, or over
longer time-frames may result from inconsistent adherence to
dietary treatment, failure to adjust treatment to changes in
growth rate and catabolism associated with illness.
Although it has been suggested that Phe ﬂuctuations may be
associated with poorer outcomes, the mechanism by which
ﬂuctuations may affect outcomes is not known(72). Fluctuations
in Phe levels are implicated as a factor inﬂuencing IQ and
cognitive performance in PKU(6,79–81). In adults, stability of Phe
levels may be as important as absolute Phe levels for cognitive
outcomes(6,81). International guidelines do not speciﬁcally
address Phe ﬂuctuations; however, consistently following
management plans, attention to dietary intake during inter-
current illness and measuring Phe levels at the recommended
intervals may reduce the frequency and magnitude of Phe
ﬂuctuations.
Special considerations in phenylketonuria
Improving compliance to amino acid feeding
Adherence with diet is fundamental to successful treatment of
PKU, and non-adherence represents a major cause of blood Phe
levels outside of recommended ranges(73). Poor adherence can
also have negative effects on overall health status if there is low
and inconsistent intake of a macro- and micronutrient-
supplemented amino acid mixture.
PKU represents a substantial burden(82). The need to severely
reduce the intake of protein-rich foods, access special low-
protein modiﬁed foods, prepare special meals, and monitor and
calculate the dietary protein/Phe intake can be particularly
onerous for both carers and patients(15,83–85). This is further
compounded by the need to administer multiple daily doses of
free amino acid mixtures that some patients ﬁnd distasteful.
Despite efforts to improve palatability, the development of an
amino acid mixture with organoleptic properties acceptable to
all patients remains a challenge. This is particularly important
among older patients who have low adherence rates(15), and
may have stopped diet treatment because of difﬁculties in
accepting and tolerating amino acid supplements.
Phenylalanine tolerance
Depending on the amount of residual PAH activity associated
with a patient’s genotype, there is considerable variation in the
amount of natural protein (Phe) that patients can tolerate while
maintaining blood Phe levels in the recommended range.
Increasing Phe tolerance may improve adherence to treatment
and quality of life by allowing the intake of more natural foods.
A subgroup of patients with PKU, comprising mainly those with
mild/moderate disorder, is responsive to pharmacological
treatment with BH4. This can minimise dietary restrictions by
allowing higher intake of natural protein(86,87); however, there
is a risk of micronutrient deﬁciencies due to the decrease in the
intake of vitamin and mineral-supplemented Phe-free L-amino
acid mixtures(88). Careful monitoring is still required to ensure
that the diet is nutritionally adequate, and long-term long-
itudinal studies are needed to understand the real impact of BH4
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Towards a physiological amino acid absorption
Two different approaches have been hypothesised to deliver free
amino acid mixtures with physiological absorption kinetics:
existing free amino acid mixtures could be administered
throughout the day, or methods could be developed to prolong
the gut transit time and/or absorption kinetics of the amino acid
mixture to simulate the physiological absorption of intact protein.
The ﬁrst approach involves giving a more evenly distributed
amino acid mixture over 24 h, including a nocturnal dose(78).
However, this will create problems with adherence by com-
plicating treatment because of the increased number of doses to
plan and remember, going against the unmet needs and desires
expressed by patients and carers to improve quality of life by
simplifying therapy and normalising the social context of
treatment(89–91).
The second approach requires the development of a
sustained-release formulation that provides a physiological
absorption proﬁle similar to that of intact natural proteins, or a
controlled-release system that maintains blood amino acid levels
above a certain threshold for an extended period. This would not
only improve the balance between anabolism and catabolism
induced by amino acids, but ideally might also simplify therapy
by reducing the number of amino acid mixture administrations.
However, such technology must not have deleterious effects on
overall digestion. Moreover, regardless of the strategy used to
modify amino acid absorption, care must be taken not to disrupt
the intricate amino acid signalling mechanisms involved in
digestive secretion, motility and the gut–brain axis.
Discussion
Despite recent improvements, more than half of patients with PKU
report that managing their disorder is ‘difﬁcult’. Moreover,
although it has been recommended in the US guidelines since
2000, a recent study showed that one in four patients < 18 years
of age do not maintain Phe levels < 360 μmol/l, and non-
controlled adults constitute almost two-thirds of the surveyed PKU
population(91). Surveyed patients identiﬁed neurocognitive issues
with attention, memory, executive functions, depression, anxiety
and mood disturbances among the most important symptoms to
improve(91). Whether physiological absorption of amino acids has
any effects on Phe-level control remains to be demonstrated;
however, even a small improvement in Phe tolerance would be
especially relevant for patients with very high untreated blood Phe
levels. The aim of the present review was to discuss how an
improved N balance in patients with PKU might theoretically
make an impact on patients, and how such a goal may be reached
by modifying the absorption of the free amino acids that patients
with PKU utilise every day. However, this issue is also relevant to
other conditions that require a protein-restricted diet supple-
mented with a speciﬁc amino acid mixture, such as tyrosinaemia,
maple syrup urine disease and perhaps homocystinuria.
Amino acid absorption proﬁles represent an area of disease
control that has received little attention. We believe that
prolonging the absorption of free amino acids may help to
maintain a positive N balance and reduce catabolic episodes
during the 24 h cycle, supporting optimal growth in children
and the maintenance of muscle mass in adults. Better utilisation
of amino acids entering the blood gradually might sustain more
efﬁcient anabolism and at the same time reduce the amount of
amino acids that are oxidised because of the sudden excess of
these nutrients after the consumption of a protein substitute
dose. This hypothesis is supported by studies that suggest that
the accumulation of lean mass is associated with the amount of
intact protein in the PKU diet(92,93). However, in the study by
Jani et al.(93), improvements in lean body mass and the ratio of
lean:fat body mass seen with a higher intake of intact protein
were accompanied by high mean blood Phe values of
870 μmol/l among adults and 613 μmol/l among children.
Therefore, simply increasing the intake of typical intact protein
is not a viable solution. An ideal protein source for PKU would
be a ‘slow’ protein with no or very low levels of Phe, high levels
of Tyr and perhaps other LNAA, and a normal composition of
the other amino acids. Such a protein would not require sup-
plementation with free amino acids, other than Phe. A natural
protein with these characteristics has not been identiﬁed and
producing it through recombinant methods would not be eco-
nomically feasible; in either case, it would need to be puriﬁed.
Glycomacropeptide (GMP), a sixty-four-amino acid peptide
released from casein during cheese production, has some of the
characteristics sought. However, commercial GMP does contain
a small amount of Phe. Also, because pure GMP lacks the
essential amino acids histidine and tryptophan, the semi-
essential amino acids arginine, and cysteine, and the con-
ditionally essential amino acid Tyr, they must be added as free
amino acids to GMP protein substitutes. GMP is a small acid-
soluble peptide isolated from the whey fraction, and is thus a
‘fast’ protein. Nonetheless, results of a study in eleven patients
revealed lower blood urea N and higher postprandial blood
amino acid levels compared with the standard PKU diet sup-
plemented with a free amino acid mixture(94), suggesting that a
strategy providing physiological absorption of all non-Phe
amino acids is worth pursuing.
Modifying the disposition and distribution of amino acids to
resemble what occurs after ingestion of intact protein may
promote a balanced transport of LNAA across the BBB for
extended periods, thereby contrasting the preferential inﬂux of
Phe into the brain because of its high afﬁnity for the LAT1
transporter. As a consequence, brain essential amino acid
concentrations may be more balanced, with an effect on neu-
rotransmitter synthesis and in turn plausible positive con-
sequences on neurocognitive outcomes.
In addition to existing strategies to relieve the burden of PKU,
including supplements with improved palatability, GMP-based
products, LNAA supplementation and BH4 therapy for those
who respond, the availability of an amino acid mixture with
absorption-prolonging features warrants further investigation
and validation of clinical beneﬁts in PKU patients.
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